KR20230107309A - 항-gdf15 항체 및 암 치료용 투여 용법 - Google Patents
항-gdf15 항체 및 암 치료용 투여 용법 Download PDFInfo
- Publication number
- KR20230107309A KR20230107309A KR1020237019624A KR20237019624A KR20230107309A KR 20230107309 A KR20230107309 A KR 20230107309A KR 1020237019624 A KR1020237019624 A KR 1020237019624A KR 20237019624 A KR20237019624 A KR 20237019624A KR 20230107309 A KR20230107309 A KR 20230107309A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- cancer
- amino acid
- gdf
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206801.1 | 2020-11-10 | ||
| EP20206801 | 2020-11-10 | ||
| EP21175107 | 2021-05-20 | ||
| EP21175107.8 | 2021-05-20 | ||
| EP21196910.0 | 2021-09-15 | ||
| EP21196910 | 2021-09-15 | ||
| PCT/EP2021/081236 WO2022101263A1 (en) | 2020-11-10 | 2021-11-10 | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230107309A true KR20230107309A (ko) | 2023-07-14 |
Family
ID=78500639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237019624A Pending KR20230107309A (ko) | 2020-11-10 | 2021-11-10 | 항-gdf15 항체 및 암 치료용 투여 용법 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20240043517A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4778537A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7879142B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107309A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021376864A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200687A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4243928T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3071749T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4243928T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20260635T1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302646A (cg-RX-API-DMAC7.html) |
| LT (1) | LT4243928T (cg-RX-API-DMAC7.html) |
| PL (1) | PL4243928T3 (cg-RX-API-DMAC7.html) |
| RS (1) | RS68123B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI4243928T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202600256T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022101263A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021111636A1 (ja) | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗gdf15抗体 |
| LT4243928T (lt) | 2020-11-10 | 2026-06-10 | Catalym Gmbh | Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui |
| EP4584293A1 (en) | 2022-09-08 | 2025-07-16 | CatalYm GmbH | Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer |
| WO2024126808A1 (en) | 2022-12-16 | 2024-06-20 | Catalym Gmbh | Anti-gdf 15 antibody for neoadjuvant therapy of cancer |
| CN116462757A (zh) | 2023-03-24 | 2023-07-21 | 科兴生物制药股份有限公司 | Gdf15的单域抗体及其应用 |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| CA2372119A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily |
| US7141661B2 (en) | 2000-09-08 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| ES2689328T3 (es) | 2004-01-07 | 2018-11-13 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpo monoclonal M-CSF-específico y usos del mismo |
| DK2441466T3 (da) | 2004-04-13 | 2014-10-27 | St Vincents Hosp Sydney | MIC-1-inhiberende middel |
| US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| CN101896192A (zh) | 2007-10-09 | 2010-11-24 | 圣文森特医院悉尼有限公司 | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 |
| WO2009150256A1 (en) | 2008-06-13 | 2009-12-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Markers for predicting response and survival in anti-egfr treated patients |
| CA2737636A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| CA2737597C (en) | 2008-10-16 | 2017-03-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| US7736861B1 (en) | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| EP2388594A1 (en) | 2010-05-17 | 2011-11-23 | Roche Diagnostics GmbH | GDF-15 based means and methods for survival and recovery prediction in acute inflammation |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| EP2506015A1 (en) | 2011-04-01 | 2012-10-03 | Universität Regensburg | A prognostic and therapeutic signature for malignant melanoma |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| AU2013322628B2 (en) | 2012-09-26 | 2017-03-02 | Julius-Maximilians-Universitat Wurzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15) |
| ES3066738T3 (en) | 2012-12-21 | 2026-05-14 | Aveo Pharmaceuticals Inc | Anti-gdf15 antibodies |
| US11021752B2 (en) | 2013-03-15 | 2021-06-01 | Myriad Genetics, Inc. | Genes and gene signatures for diagnosis and treatment of melanoma |
| WO2015108907A2 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| ES2712201T3 (es) | 2014-01-28 | 2019-05-09 | Hoffmann La Roche | Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| PT3653644T (pt) | 2014-03-26 | 2023-12-19 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro |
| EP3851122A1 (en) * | 2014-09-25 | 2021-07-21 | Aveo Pharmaceuticals Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| EP3073268A1 (en) | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
| EP3356827B1 (en) | 2015-10-02 | 2023-12-06 | Julius-Maximilians-Universität Würzburg | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| GB201517528D0 (en) | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| KR102722730B1 (ko) * | 2015-10-02 | 2024-10-25 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법 |
| US11072657B2 (en) | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| JP7138567B2 (ja) * | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子15に対する抗体およびそれらの使用 |
| CN112912395B (zh) | 2018-08-20 | 2024-08-23 | 辉瑞公司 | 抗gdf15抗体、组合物和使用方法 |
| US20230212274A1 (en) | 2020-02-21 | 2023-07-06 | The Children's Medical Center Corporation | Method for treating asthma or allergic disease |
| CN114560938B (zh) | 2020-03-30 | 2023-05-23 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
| LT4243928T (lt) | 2020-11-10 | 2026-06-10 | Catalym Gmbh | Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui |
-
2021
- 2021-11-10 LT LTEPPCT/EP2021/081236T patent/LT4243928T/lt unknown
- 2021-11-10 RS RS20260613A patent/RS68123B1/sr unknown
- 2021-11-10 EP EP26167595.3A patent/EP4778537A2/en active Pending
- 2021-11-10 ES ES21801956T patent/ES3071749T3/es active Active
- 2021-11-10 KR KR1020237019624A patent/KR20230107309A/ko active Pending
- 2021-11-10 CA CA3200687A patent/CA3200687A1/en active Pending
- 2021-11-10 FI FIEP21801956.0T patent/FI4243928T3/fi active
- 2021-11-10 PL PL21801956.0T patent/PL4243928T3/pl unknown
- 2021-11-10 AU AU2021376864A patent/AU2021376864A1/en active Pending
- 2021-11-10 DK DK21801956.0T patent/DK4243928T3/da active
- 2021-11-10 IL IL302646A patent/IL302646A/en unknown
- 2021-11-10 WO PCT/EP2021/081236 patent/WO2022101263A1/en not_active Ceased
- 2021-11-10 EP EP21801956.0A patent/EP4243928B1/en active Active
- 2021-11-10 SI SI202130431T patent/SI4243928T1/sl unknown
- 2021-11-10 SM SM20260256T patent/SMT202600256T1/it unknown
- 2021-11-10 JP JP2023550715A patent/JP7879142B2/ja active Active
- 2021-11-10 HR HRP20260635TT patent/HRP20260635T1/hr unknown
-
2023
- 2023-05-10 US US18/314,940 patent/US20240043517A1/en not_active Abandoned
-
2025
- 2025-05-15 US US19/208,792 patent/US12497447B2/en active Active
- 2025-11-06 US US19/381,711 patent/US20260055172A1/en active Pending
Non-Patent Citations (17)
| Title |
|---|
| Abulizi P, Loganathan N, Zhao D, et al. Growth Differentiation Factor-15 Deficiency Augments Inflammatory Response and Exacerbates Septic Heart and Renal Injury Induced by Lipopolysaccharide Sci Rep. 2017;7(1):1-10. |
| Bottner, Martina, Martin Laaff, Birgit Schechinger, Gudrun Rappold, Klaus Unsicker, and Clemens Suter-Crazzolara. 1999. "Characterization of the Rat, Mouse, and Human Genes of Growth/Differentiation Factor-15/Macrophage Inhibiting Cytokine-1 (GDF-15/MIC-1)." Gene 237 (1): 105-11. |
| Chung HK, Kim JT, Kim HW, et al. GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep. 2017;7(1):1-13. doi:10.1038/s41598-017-17574-w |
| Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. |
| Emmerson, Paul J., Feng Wang, Yong Du, Qian Liu, Richard T. Pickard, Malgorzata D. Gonciarz, Tamer Coskun, et al. 2017. "The Metabolic Effects of GDF15 Are Mediated by the Orphan Receptor GFRAL." Nature Medicine 23 (10): 1215-19. https://doi.org/10.1038/nm.4393. |
| Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 Mar 20;36(9):850-858. |
| Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1. Nat Med. 2007;13(11):1333-1340. doi:10.1038/nm1677 |
| Kempf, Tibor, Alexander Zarbock, Christian Widera, Stefan Butz, Anika Stadtmann, Jan Rossaint, Matteo Bolomini-Vittori, et al. 2011. "GDF-15 Is an Inhibitor of Leukocyte Integrin Activation Required for Survival after Myocardial Infarction in Mice." Nature Medicine 17 (5): 581-88. https://doi.org/10.1038/nm.2354. |
| Selby, Mark J., John J. Engelhardt, Robert J. Johnston, Li-Sheng Lu, Minhua Han, Kent Thudium, Dapeng Yao, et al. 2016. "Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology." Edited by Aamir Ahmad. PLOS ONE 11 (9): e0161779. https://doi.org/10.1371/journal.pone.0161779. |
| Tong S, Marjono B, Brown DA, et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet. 2004;363(9403):129-130. doi:10.1016/S0140-6736(03)15265-8 |
| Tsai, Vicky W.W., Yasmin Husaini, Amanda Sainsbury, David A. Brown, and Samuel N. Breit. 2018. "The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases." Cell Metabolism 28 (3): 353-68. https://doi.org/10.1016/j.cmet.2018.07.018. |
| van den Boorn, Jasper G., and Gunther Hartmann. 2013. "Turning Tumors into Vaccines: Co-Opting the Innate Immune System." Immunity 39 (1): 27-37. https://doi.org/10.1016/j.immuni.2013.07.011. |
| Vaupel, Peter. 2004. "Tumor Microenvironmental Physiology and Its Implications for Radiation Oncology." Seminars in Radiation Oncology 14 (3): 198-206. https://doi.org/10.1016/j.semradonc.2004.04.008. |
| Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018;32(3):1537-49. |
| Welsh, John B., Lisa M. Sapinoso, Suzanne G. Kern, David A. Brown, Tao Liu, Asne R. Bauskin, Robyn L. Ward, et al. 2003. "Large-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum." Proceedings of the National Academy of Sciences 100 (6): 3410-15. https://doi.org/10.1073/PNAS.0530278100. |
| Wischhusen J, Melero I, and Fridman W. GDF-15: From Biomarker to Novel Targetable Immune Checkpoint. Front. Immunol. Accepted 23 Apr 2020. doi: 10.3389/fimmu.2020.00951. |
| Wollert KC, Kempf T, Giannitsis E, et al. An Automated Assay for Growth Differentiation Factor 15. J Appl Lab Med An AACC Publ. 2018;1(5):510-521. doi:10.1373/jalm.2016.022376. |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022101263A1 (en) | 2022-05-19 |
| EP4243928A1 (en) | 2023-09-20 |
| EP4243928B1 (en) | 2026-04-22 |
| SMT202600256T1 (it) | 2026-07-16 |
| US20240043517A1 (en) | 2024-02-08 |
| EP4778537A2 (en) | 2026-07-22 |
| HRP20260635T1 (hr) | 2026-06-19 |
| JP7879142B2 (ja) | 2026-06-23 |
| ES3071749T3 (en) | 2026-06-25 |
| FI4243928T3 (fi) | 2026-06-04 |
| SI4243928T1 (sl) | 2026-07-31 |
| US12497447B2 (en) | 2025-12-16 |
| AU2021376864A1 (en) | 2023-06-29 |
| DK4243928T3 (da) | 2026-05-26 |
| JP2023548430A (ja) | 2023-11-16 |
| CA3200687A1 (en) | 2022-05-19 |
| US20250282858A1 (en) | 2025-09-11 |
| LT4243928T (lt) | 2026-06-10 |
| PL4243928T3 (pl) | 2026-08-03 |
| RS68123B1 (sr) | 2026-06-30 |
| IL302646A (en) | 2023-07-01 |
| US20260055172A1 (en) | 2026-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497447B2 (en) | Anti-GDF15 antibody and a dosage regimen for the treatment of cancer | |
| JP2022535564A (ja) | 多選択性タンパク質 | |
| US11440959B2 (en) | CD226 agonist antibodies | |
| CN113301961A (zh) | 给予抗tim-3抗体的方法 | |
| US20250320268A1 (en) | Clinical dosing of sirp1a chimeric protein | |
| JP2024544972A (ja) | Sirp1a及びcd40lベースのキメラタンパク質 | |
| EP4624493A1 (en) | Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr | |
| CN116848137A (zh) | 抗gdf15抗体以及用于治疗癌症的给药方案 | |
| KR20240058149A (ko) | Vista 항원-결합 분자를 사용한 암의 치료 및 예방 | |
| JP2021529777A (ja) | 進行非小細胞肺癌の治療のための標的TGF−β阻害による組み合わせ療法 | |
| JP2021523096A (ja) | 未治療対象において癌を治療する際に使用するための標的tgf−β阻害のための投与計画 | |
| CN118541395A (zh) | 用her3抗原结合分子治疗和预防癌症 | |
| AU2022264597A9 (en) | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy | |
| AU2024368294A1 (en) | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein | |
| EA053205B1 (ru) | Антитело против gdf15 и режим дозирования для лечения злокачественного новообразования | |
| CN118613280A (zh) | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 | |
| US20250304673A1 (en) | Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer | |
| US20260042817A1 (en) | Pet tracer for detection of transforming growth factor beta | |
| KR20240022608A (ko) | 항-tgf-베타 항체 제형 및 이의 용도 | |
| WO2024173352A2 (en) | Methods of treating cancer with a sirp1a-based chimeric protein | |
| CN119562830A (zh) | 抗体组合物及其使用方法 | |
| TW202241513A (zh) | 一種包含抗體融合蛋白的醫藥組成物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |